Predictors of survival, healthcare resource utilization, and healthcare costs in veterans with non-metastatic castration-resistant prostate cancer-Reference-Cited by-同舟云学术

Predictors of survival, healthcare resource utilization, and healthcare costs in veterans with non-metastatic castration-resistant prostate cancer

Published:2020-12 Issue:12 Volume:38 Page:930.e13-930.e21
ISSN:1078-1439
Container-title:Urologic Oncology: Seminars and Original Investigations
language:en
Short-container-title:Urologic Oncology: Seminars and Original Investigations

Author:

Freedland Stephen J.,Pilon Dominic,Bhak Rachel H.,Lefebvre Patrick,Li Sophia,Young-Xu Yinong

Funder

Janssen Scientific Affairs, LLC, Titusville, NJ

Publisher

Elsevier BV

Subject

Urology,Oncology

Reference25 articles.

1. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology - Prostate Cancer Version 4. Updated August 15, 2018, 2018. Available from: https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf.

2. Tackling non-metastatic castration-resistant prostate cancer: special considerations in treatment;Anantharaman;Expert Rev Anticancer Ther,2017

3. Non-metastatic castrate-resistant prostate cancer: a call for improved guidance on clinical management;Rozet;World J Urol,2016

4. Validation of a bone scan positivity risk table in non-metastatic castration-resistant prostate cancer;Freedland;BJU Int,2016

5. Elevated alkaline phosphatase velocity strongly predicts overall survival and the risk of bone metastases in castrate-resistant prostate cancer;Metwalli;Urol Oncol,2014

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real-world economic burden associated with disease progression from metastatic castration-sensitive to castration-resistant prostate cancer on treatment in the United States;Journal of Managed Care & Specialty Pharmacy;2024-07

2. Survival and Economic Impact of Rapid Prostate-Specific Antigen Doubling Time in Patients With Nonmetastatic Castration-Resistant Prostate Cancer;Clinical Genitourinary Cancer;2023-08

3. Predicting Acute Care Events Among Patients Initiating Chemotherapy: A Practice-Based Validation and Adaptation of the PROACCT Model;JCO Oncology Practice;2023-08

4. Prevalence and Natural History of Non-metastatic Castrate Resistant Prostate Cancer: A Population-Based Analysis;Clinical Genitourinary Cancer;2023-04

5. Efficacy and Safety of Darolutamide in Patients with Nonmetastatic Castration-resistant Prostate Cancer Stratified by Prostate-specific Antigen Doubling Time: Planned Subgroup Analysis of the Phase 3 ARAMIS Trial;European Urology;2023-03